Most people who stop GLP-1 treatment eventually restart

GLP-1 readers see the stop-restart question in the real world whenever a treatment pause, a price change or a provider switch gets in the way of a smooth month.

A new analysis of more than 60,000 patients found that 4 in 10 stopped GLP-1 treatment within the first year, and 6 in 10 had stopped by year two. The striking part is what happened next: more than half of those who stopped restarted within a year of pausing, and around 58% had restarted within two years.

That is not a failure story. It is a reminder that treatment journeys change, and many people come back once the pause ends or a better route is found.

Why people pause

Some pauses are planned. Others happen when side effects, supply, payment timing or a change in routine gets in the way. The key point is that a pause does not always mean the treatment is over.

Why restart matters

The restart figure matters because it changes the way provider pages should be read. If a provider makes switching, repeat review or maintenance support easy to understand, it may be better placed for the real world than a page that only leads with the first checkout number.

What this means when you compare providers

• Look for clear repeat-review or maintenance wording.
• Check whether the page explains switching or restarting after a break.
• See whether delivery, support and follow-up are visible before the CTA.
• Compare the route, not only the starting price.

Weight Loss Comparison readers should also think about the practical side of a pause: do you know where the next consultation comes from, how a restart is handled and whether the provider helps you pick up where you left off?

That is why the most useful next step is to open the comparison page and then move to the maintenance or support guidance before choosing a provider.

Source: ScienceDaily / ENDO 2026. Published 18 June 2026.